While anti-PD-1 monotherapy did not significantly affect tumor growth compared to controls, combining anti-PD-1 with THT significantly reduced tumor volume, yielding results comparable to THT plus i.t. IL-2 (Figure 6I). This evidence concerns the gene IL2 and neoplasm.